Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma & banking major losers
Fri, 10 Apr 01:30 pm

Indian markets extended their losses as investors await reports on India's Industrial production. Indian markets remained volatile. BSE Sensex fell over 50 points while NSE-Nifty fell about 18 points. BSE Mid Cap and BSE Small Cap stocks have outperformed the markets with gains of 0.7% and 0.8%, respectively. Healthcare sector has been the biggest loser among all the sectoral indices. Consumer Durable stocks gained the maximum with gains of over 0.7%.

Commodities are trading with moderate gains. Gold prices gained 0.13% or Rs 35 while silver prices gained 0.5% or Rs 171. While gold price, per 10 grams, is trading near Rs 26,550 level; silver price, per kilogram, is trading near Rs 36,450 level. Crude oil price fell about 1% viz Rs 34 and per barrel is available at Rs 3,181. Dollar gained about 0.2% and is available at Rs 62.38 against the Indian Rupee.

The pharmaceutical sector has been trading weak. Sun Pharma has seen profit booking since a couple of days. Glenmark Pharmaceuticals said that the US health regulator has allowed Glenmark's US arm - Glenmark Generics for issuance of oral contraceptive medicine named Levonorgestrel/ Ethinyl Estradiol tablets of 0.09 mg/0.02 mg. According to a leading financial source, this is the 11th medicine that is authorized by the US FDA for distribution. The stock of Glenmark Pharma is trading up by 0.5%.

Banking stocks are trading in the red. Indusind Bank has said that that it will be taking over Royal Bank of Scotland's (RBS) diamond and jewellery financing business. RBS had acquired ABN AMRO in 200.7 According to a leading financial source, diamond and jewellary business of Royal Bank of Scotland is estimated to be nearly Rs 45 bn. The stock is trading down 0.4%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Pharma & banking major losers". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.